Prostate Cancer Postdoctoral Training Program
Prostate cancer research at Cedars-Sinai encompasses everything from molecular genetics, biochemical analyses and comparative animal research, to clinical investigation, therapeutic trials and health services research.
Prostate cancer is the second leading cause of cancer-related death in males in the U.S., with 174,650 new cases and 31,620 deaths estimated in 2019. There is great promise in prevention, early detection, distinction of indolent and aggressive disease, and novel treatments. Many unmet clinical needs require better understanding of:
- Prostate cancer genomics and signaling
- How the tumor interacts with its microenvironment
- The development of novel therapeutics strategies
- Understanding risk factors
- Variations in treatment patterns that lead to optimal care delivery
We are looking for highly motivated trainees for our Prostate Cancer Training Program T32 supported by the NCI/NIH. Our primary objective is to help fellows become productive research scientists capable of establishing independent scientific careers in prostate cancer research.
Interviews are by invitation. Cedars-Sinai doesn't discriminate on the basis of sex, race, color, or national or ethnic origin.
The genitourinary cancer tumor boards include medical, surgical, radiation oncologists, pathologists, and many other disciplines, as well as fellows. Patient cases, radiology images, and pathology results are reviewed and experts recommend the best course of treatment and a care plan is developed.
Prostate cancer clinical trials underway at Cedars-Sinai explore various facets of the disease, including possible new treatment options—from surgery to radiation—as well as new diagnostic, imaging and genetic-based advancements.
The mentors of this unique and collaborative training program are committed to training young scientists in interdisciplinary translational research. The faculty, at the forefront of prostate cancer research and patient care, are united in recruiting and training talented minds that will perform interdisciplinary research at the Samuel Oschin Comprehensive Cancer Institute.
He introduced the concept of paracrine-mediated tumor initiation, particularly resulting from alterations in TGF-ß signaling. He has mentored 23 research trainees; 13 now in faculty positions in the past decade. Twelve of the trainees gained extramural postdoctoral funding.
His lab pioneered research in paracrine factors mediating epithelial-mesenchymal interaction and androgen receptor signaling regulating prostate cancer progression, including its role in distant metastasis. He has mentored 30 trainees in the last decade, with 19 in faculty positions.
He is a Urologist with a clinical focus on prostate cancer and Department of Defense supported research on age and co-morbidity of prostate cancer patients. His research also includes treatment decision-making for early stage prostate cancer. He is the Director of Health Services Research for the Cedars-Sinai Department of Surgery. He is an In-Training mentor.
Her group has developed the tools to selectively purify large oncosomes from other types of extracellular vesicles and has obtained evidence that large oncosomes convey novel biological information within the tumor microenvironment.
Her research seeks to understand how environmental and genetic factors affect the development, treatment and prevention of cancer, especially in minorities. Her studies examine risk factors and long-term outcomes for colorectal, prostate and breast cancer. She is Director of Community and Population Health Sciences.
A urologist who studies risk stratification, health disparities, and the role of lifestyle and obesity on prostate cancer. He directs the Center for Integrated Research in Cancer and Lifestyle and is the associate director for faculty development. He has >500 papers and has trained 16 fellows (9 have faculty positions) and multiple junior faculty.
His lab studies mechanisms of prostate cancer progression, including the use of bioinformatics resources to define prostate tumor status to guide therapeutic decisions. He has trained 7 independent faculty members in the past 10 years, with over 35 faculty in his career.
Her research focuses on mitochondrial turnover in cardiac muscle. Her findings impact our understanding of obesity, diabetes and cancer. She developed mechanisms of modulating autophagy and tracking mitochondrial oxidative status. She has trained 15 postdoctoral fellows and 7 have faculty positions.
He is a leader in cancer disparities in the Asian and Hispanic populations and the Associate Director for Population Sciences. He has originated multiple large cohort studies for colon cancer. Since his recent move to Cedars-Sinai, the unique differences in prostate cancer disease progression in Asians and Hispanics is a new area of interest.
He is Chief of Academic Urology at Cedars-Sinai. His clinical practice focuses on treating prostate cancer and other urological cancers. His laboratory develops strategies for stimulating a cancer immune response and developing imaging tools for diagnostics. He has trained 10 fellows, with 1 currently in an academic faculty position.
His laboratory designs nanoparticles for biomedical imaging, diagnostics and therapy. Some of the original prostate cancer targeted nanoparticle theranostics originated from the Perez lab.
Practicing GU Oncologist with laboratory-based research focused on signal transduction inhibitor therapy for metastatic prostate cancer. As Uro-oncology program medical director, he facilitates investigators in the program to translate basic and clinical findings alike. He has trained 4 fellows, each of whom received extramural support.
He is an immunologist and practicing radiation oncologist with a focus on breast and brain cancer. He studies the inflammatory cascade following radiation therapy in murine models with the goal of translating these findings. He is currently working closely with Leland Chung and Stephen Freedland to test the application to prostate cancer.
She is a health services researcher focusing on understanding how racial differences in inflammation and obesity may in part be responsible for the disproportionally higher prostate cancer incidence and mortality rates in African-Americans. Her work is supported by a recent American Cancer Society grant. She is an In-Training mentor.
Contact us if you have questions or would like to learn more about Cedars-Sinai Prostate Cancer NIH Funded Training Program.
Neil Bhowmick, PhD
Professor and Co-Director of Cancer Biology
8750 Beverly Blvd., Atrium Building Rm 103
Los Angeles, CA 90048
Stephen Freedland, MD
Professor and Co-Director of Prevention and Control
8500 Beverly Blvd., East Tower
Los Angeles, CA 90048